The Consumer Ascent on A290650 (A290650)
公司名称 L&C BIO
主要经营地 KR
详细生意模式 Re2O注射式胶原蛋白补充剂，相比Rejuran溢价80-170%，6个月内诊所数500→2,000+
护城河 🟡中
估值水平 收盘价₩67,300, 目标价₩96,000(+37%)；P/E隐含30-35x，高增长定价但风险集中
EV/Market Cap ₩1,672B
网络观点 Re2O溢价定位反映品质认可，快速诊所网络扩张
AI观点 同意增长，但补充：皮肤科消费品竞争加剧，溢价维持靠持续创新和品牌；目标价隐含高增长，需谨慎现金流验证
作者简介 Norbu Capital消费品研究，关注亚洲美容医疗创新
Automatically collect high-quality investment opinions from across the web daily
Over 50+ high-quality investment ideas await you every day
Investment insights from 15+ platforms like Substack, Seeking Alpha, X/Twitter, with AI-powered summaries, categorized by industry. Register for free to access all features.